KalVista Pharmaceuticals, Inc. (KALV)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$125.0M
Cash & Equivalents
$14.5M
Quarterly Burn Rate
26 mo
Est. Cash Runway
$1,426M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
SEBETRALSTAT
EKTERLY |
APPROVED | Angioedema, Hereditary, Types I and II, Diabetic Macular Edema, Hereditary Angioedema |
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05511922 | PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial | PHASE3 | Active Not Recruiting | 11 |
| NCT05505916 | An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angio... | PHASE3 | Active Not Recruiting | 145 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.